GSK and oth­ers delist Or­ange Book patents af­ter FTC tar­gets pro­tec­tions on in­halers and ep­i­neph­rine in­jec­tors

Three phar­ma com­pa­nies have agreed to delist some of the patents chal­lenged by the Fed­er­al Trade Com­mis­sion in No­vem­ber, part of a push by the agency to tar­get prac­tices it claims are lim­it­ing com­pe­ti­tion.

GSK agreed to delist 12 of 14 patents iden­ti­fied by the FTC, plus an ad­di­tion­al five more “in light of evolv­ing poli­cies and de­vel­op­ments in the law re­gard­ing the list­ing of drug-de­vice com­bi­na­tions,” ac­cord­ing to a let­ter sent Thurs­day from law­mak­ers to FDA Com­mis­sion­er Rob Califf, which out­lined the changes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER